| Budget Amount *help |
¥24,310,000 (Direct Cost: ¥18,700,000、Indirect Cost: ¥5,610,000)
Fiscal Year 2018: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
Fiscal Year 2017: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
Fiscal Year 2016: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Outline of Final Research Achievements |
Anti-platelet factor 4 (PF4)/heparin antibodies-induced platelet activation is important for thrombosis in heparin-induced thrombocytopenia (HIT), and we established in vitro functional HIT assay system using mouse anti-PF4/heparin monoclonal antibody (HIT-MoAb).
We have found that platelet activation via the clustering of FcγRIIa involves cytochalasin-sensitive cytoskeletal reorganization and that cytochalasin B (CB) significantly enhanced HIT-MoAb-induced platelet activation, accompanied by platelet aggregation. From a practical viewpoint, CB may be useful for improving the sensitivity of HIT functional assays. We have also developed a facile immunological HIT assay system, which can be applied to IVD in the future.
|
